Policy

11/15/24

The way forward for therapeutics value assessment

Biotech

Policy

11/13/24

Managing pain without opioids is on the horizon – if we decide it’s worth it

Biotech

Policy

Science

10/14/24

The political rot eroding our national health security

Biotech

Policy

06/20/24

When it comes to global drug sales, all revenue is not created equal

Biotech

Culture

Policy

06/12/24

Discount rates and drug value: A Q&A with Josh Cohen

Finance

Policy

Biotech

05/03/24

Join the Quest for GCEA and Affordable Innovation at ISPOR 2024 with No Patient Left Behind

Biotech

Policy

04/29/24

Now boarding: Net-zero aviation

Policy

Science

Planetary

04/23/24

Eroding tolerance: A wonder drug shows us the drug industry’s fundamental failure to communicate

Biotech

Culture

Policy

03/25/24

Battling the consequences of price controls at high altitude

Biotech

Policy

03/21/24

Talking Trash 2: Getting Scrappy

Policy

Planetary

03/18/24

US biosecurity starts at home, with insurance reform aimed at making innovation affordable

Biotech

Policy

12/09/23

Talking Trash 1: Why Sortation Matters

Policy

Planetary

11/30/23

Egypt and hepatitis C cures — the gift that keeps on giving

Biotech

Policy

11/22/23

Can the European scorpion hold its sting?

Biotech

Policy

11/21/23

Want lower obesity drug costs? Medicare holds the key

Biotech

Policy

05/05/23

Do we value curbing carbon emissions more than curing cancer?

Biotech

Policy

05/03/23

Toxic math: a British export that the US mustn’t import

Biotech

Policy

03/23/23

Why fixing the IRA matters to all of us

Biotech

Policy

03/12/23

Act now to prevent SVB’s failure from becoming a national crisis

Biotech

Finance

Policy

Planetary

12/21/22

What you were reading — RApport’s 2022 Top Ten

Culture

Finance

Policy

Science